We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cesca Therapeutics (KOOL) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Cesca Therapeutics (KOOL - Free Report) closed the most recent trading day at $0.30, moving -1.68% from the previous trading session. This move lagged the S&P 500's daily loss of 0.63%. At the same time, the Dow lost 0.43%, and the tech-heavy Nasdaq lost 1.04%.
Heading into today, shares of the company had lost 29.47% over the past month, lagging the Medical sector's loss of 6.18% and the S&P 500's loss of 6.28% in that time.
Wall Street will be looking for positivity from KOOL as it approaches its next earnings report date. This is expected to be November 13, 2018. The company is expected to report EPS of -$0.10, up 58.33% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.97 million, down 3.26% from the year-ago period.
Investors should also note any recent changes to analyst estimates for KOOL. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. KOOL currently has a Zacks Rank of #3 (Hold).
Digging into valuation, KOOL currently has a Forward P/E ratio of 3.03. This valuation marks a discount compared to its industry's average Forward P/E of 32.01.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cesca Therapeutics (KOOL) Dips More Than Broader Markets: What You Should Know
Cesca Therapeutics (KOOL - Free Report) closed the most recent trading day at $0.30, moving -1.68% from the previous trading session. This move lagged the S&P 500's daily loss of 0.63%. At the same time, the Dow lost 0.43%, and the tech-heavy Nasdaq lost 1.04%.
Heading into today, shares of the company had lost 29.47% over the past month, lagging the Medical sector's loss of 6.18% and the S&P 500's loss of 6.28% in that time.
Wall Street will be looking for positivity from KOOL as it approaches its next earnings report date. This is expected to be November 13, 2018. The company is expected to report EPS of -$0.10, up 58.33% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.97 million, down 3.26% from the year-ago period.
Investors should also note any recent changes to analyst estimates for KOOL. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. KOOL currently has a Zacks Rank of #3 (Hold).
Digging into valuation, KOOL currently has a Forward P/E ratio of 3.03. This valuation marks a discount compared to its industry's average Forward P/E of 32.01.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.